Gwen Lapham, PhD, MPH, MSW, joined Kaiser Permanente Washington Health Research Institute (KPWHRI) in 2013 as an addictions health services researcher. Since then, she has capitalized on her prior social work and health services training to do impactful research on evidence-based primary care for unhealthy substance use, including alcohol, cannabis, and opioids. She has recently begun making strides in understanding cannabis use among primary care patients, including medical use and use among prenatal women.
Dr. Lapham recently completed the CATALyST K12 Washington Learning Health System Program funded by the Agency for Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute. In the program, she partnered with Kaiser Permanente Washington health system leaders and with KPWHRI’s Center for Accelerating Care Transformation to address gaps in the quality of behavioral health care for children and adolescents by developing and testing an integrated approach to adolescent mental health. She expects this work to lead to new evidence for effective implementation of adolescent mental health integrated in primary care.
She is also a co-investigator of the Primary Care Opioid Use Disorders Treatment, or PROUD trial, a pragmatic implementation trial of nurse care management for treatment of opioid use disorders in primary care, as well as the Health Systems node of the National Institute on Drug Abuse Clinical Trials Network. Dr. Lapham’s research projects specific to cannabis include:
Prior to working at KPWHRI, Dr. Lapham focused on qualitative and quantitative evaluation of preventive alcohol interventions in medical settings at the Veterans Health Administration in Seattle.
Implementation research; quality measurement
Screening and brief intervention; mental health quality measurement
Prevention and treatment
The SPARC trial successfully implemented behavioral health care into primary care. On our website, you can access tools for behavioral health integration, as well as frequently asked questions and publications.
Williams EC, Rubinsky AD, Chavez LJ, Lapham GT, Rittmueller SE, Achtmeyer CE, Bradley KA. An early evaluation of implementation of brief intervention for unhealthy alcohol use in the U.S. Veterans Health Administration. Addiction. 2014 Sep;109(9):1472-81. doi: 10.1111/add.12600. Epub 2014 Jun 12. PubMed
Williams EC, Rubinsky AD, Lapham GT, Chavez LJ, Rittmueller SE, Hawkins EJ, Grossbard J, Kivlahan DR, Bradley KA. Prevalence of clinically recognized alcohol and other substance use disorders among VA outpatients with unhealthy alcohol use identified by routine alcohol screening. Alcohol Drug Depend. 2014 Feb 1;135:95-103. doi: 10.1016/j.drugalcdep.2013.11.016. Epub 2013 Nov 27. PubMed
Lapham GT, Rubinsky AD, Heagerty PJ, Achtmeyer C, Williams EC, Hawkins EJ, Maynard C, Kivlahan DR, Au D, Bradley KA. Probability and predictors of patients converting from negative to positive screens for alcohol misuse. Alcohol Clin Exp Res. 2014 Feb;38(2):564-71. doi: 10.1111/acer.12260. Epub 2013 Oct 7. PubMed
Delaney KE, Lee A, Lapham GT, Rubinsky AD, Chavez LJ, Bradley KA. Inconsistencies between alcohol screening results based on AUDIT-C scores and reported drinking on the AUDIT-C questions: prevalence in two national samples. Addict Sci Clin Pract. 2014 Jan 27;9(1):2. doi: 10.1186/1940-0640-9-2. PubMed
Lapham GT, Rubinsky AD, Heagerty PJ, Williams EC, Hawkins EJ, Maynard C, Kivlahan DK, Bradley KA. Annual rescreening for alcohol misuse: diminishing returns for some patient subgroups. Med Care. 2013 Oct;51(10):914-21. doi: 10.1097/MLR.0b013e3182a3e549. PubMed
Bradley KA, Chavez LJ, Lapham GT, Williams EC, Achtmeyer CE, Rubinsky AD,Hawkins EJ, Saitz R, Kivlahan DR. When quality measures undermine quality: bias in a quality measure for follow-up for alcohol misuse. Psychiatr Serv. 2013 Oct;64(10):1018-25. doi: 10.1176/appi.ps.201200449. Epub 2013 Jul 15. PubMed
Chavez LJ, Bradley KA, Lapham GT, Wickizer TM, Chisolm DJ. Identifying problematic substance use in a national sample of adolescents using frequency questions. J Am Board Fam Med. 2019;32(4):550-558. doi: 10.3122/jabfm.2019.04.180284. PubMed
1 in 5 people who use cannabis daily at risk for moderate to severe use disorder.
New grant funds crucial work to test effectiveness of teen suicide prevention in primary care.
Five years and 8 scholars later, KPWHRI celebrates the impact of the CATALyST training program on early-career scientists.
A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.
New findings indicate medical cannabis use is associated with a lower risk of moderate to severe cannabis use disorder.
CNN, Aug. 29, 2023